What The 2024 NCCN Guidelines Say About... It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

68 Ga-PSMA PET/MRI examples of PRIMARY scores. T2WI = T2-weighted image; PZ = peripheral zone; CZ = central zone. Reston, VA—PET/MRI can improve diagnostic accuracy for prostate cancer patients and ...

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Daniel Oguna, a PET CT technologist prepares a patient for a scan procedure at Aga Khan University Hospital, Nairobi. [Photo: Standard] The latest and most advanced scan for evaluation of patients ...

Global map of countries (n = 17) and the number of scanners (n = 64) that took part in phase II of the Global Variation in Magnetic Resonance Imaging Qualtiy of the Prostate (GLIMPSE) study. UK = ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...